X0206 3 2021-02-03 0 0001785345 Landos Biopharma, Inc. LABP 0001493280 WONG RODERICK C/O LANDOS BIOPHARMA, INC. 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 1 0 0 0 Series B Preferred Stock 0.00 Common Stock 3650722 I By funds Each share of the Issuer's Series B preferred stock will automatically convert into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock has no expiration date. Reflects a 1.8249-for-1 stock split of the Issuer's common stock effected on January 29, 2021. Consists of shares of common stock issuable upon conversion of Series B preferred stock held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "RTW Funds"). The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by the RTW Funds, which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the RTW Funds, except to the extent of its or his pecuniary interest therein. Exhibit List - Exhibit 24 - Power of Attorney /s/ Eric W. Blanchard, Attorney-in-Fact 2021-02-03